24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
Spotlight
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Approval
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
16:59
Born from October 7 grief, built for life: Era’s mission to transform fertility care
14:57
Grow a Garden: How a teenager’s Roblox game became the world’s most popular title
12:18
Israel’s tech workforce is shrinking. Should we worry?
12:02
Picture perfect: The best free AI image generators of 2025
More stories
Buzz
Most popular
Daily
Weekly
1
How ChatGPT pinpointed Iranian missile strikes with just Google and the news
2
Remote work’s dark side: The Soham Parekh story
3
Fab38 freeze: Intel’s big manufacturing bet collides with harsh market reality
4
Mapping Israel’s cybersecurity ecosystem: Funding doubles despite global headwinds
5
Inside Intel's painful cuts: Who's being let go and why
More news
Approval
1 stories about Approval
Market Indifferent to European Approval of Teva's Migraine Drug
02.04.19
|
Lilach Baumer
Teva's injection, one of three similar migraine drugs already approved in the U.S., is the third to receive European approval after Amgen Inc. and Novartis AG and Eli Lilly